VRNOF Quote, Financials, Valuation and Earnings

Electromed has a net margin of -124.98% compared to Verano Holdings's net margin of 12.11%. Verano Holdings's return on equity of -29.13% beat Electromed's return on equity of 15.91%.

Verano Holdings has a consensus price target of $5.50, signalling upside risk potential of 643.24%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 66.44%. Given that Verano Holdings has higher upside potential than Electromed, analysts believe Verano Holdings is more attractive than Electromed.

Verano Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Electromed has a beta of 0.460, suggesting its less volatile than the S&P 500 by 53.993%.

Verano Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verano Holdings pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Verano Holdings quarterly revenues are $218.2M, which are larger than Electromed quarterly revenues of $16.3M. Verano Holdings's net income of -$272.7M is lower than Electromed's net income of $2M. Notably, Verano Holdings's price-to-earnings ratio is -- while Electromed's PE ratio is 29.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verano Holdings is 0.29x versus 3.34x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -124.98% compared to Verano Holdings's net margin of -2.16%. Verano Holdings's return on equity of -29.13% beat Myomo's return on equity of -48.64%.

Verano Holdings has a consensus price target of $5.50, signalling upside risk potential of 643.24%. On the other hand Myomo has an analysts' consensus of $9.05 which suggests that it could grow by 169.35%. Given that Verano Holdings has higher upside potential than Myomo, analysts believe Verano Holdings is more attractive than Myomo.

Verano Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Myomo has a beta of 1.633, suggesting its more volatile than the S&P 500 by 63.336%.

Verano Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verano Holdings pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Verano Holdings quarterly revenues are $218.2M, which are larger than Myomo quarterly revenues of $12.1M. Verano Holdings's net income of -$272.7M is lower than Myomo's net income of -$260.1K. Notably, Verano Holdings's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verano Holdings is 0.29x versus 3.90x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -124.98% compared to Verano Holdings's net margin of -1226.82%. Verano Holdings's return on equity of -29.13% beat VolitionRX's return on equity of --.

Verano Holdings has a consensus price target of $5.50, signalling upside risk potential of 643.24%. On the other hand VolitionRX has an analysts' consensus of $2.92 which suggests that it could grow by 465.02%. Given that Verano Holdings has higher upside potential than VolitionRX, analysts believe Verano Holdings is more attractive than VolitionRX.

Verano Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX has a beta of 0.997, suggesting its less volatile than the S&P 500 by 0.339%.

Verano Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verano Holdings pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Verano Holdings quarterly revenues are $218.2M, which are larger than VolitionRX quarterly revenues of $474.5K. Verano Holdings's net income of -$272.7M is lower than VolitionRX's net income of -$5.8M. Notably, Verano Holdings's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verano Holdings is 0.29x versus 36.30x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -124.98% compared to Verano Holdings's net margin of -10.04%. Verano Holdings's return on equity of -29.13% beat Xtant Medical Holdings's return on equity of -35.34%.

Verano Holdings has a consensus price target of $5.50, signalling upside risk potential of 643.24%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 225.89%. Given that Verano Holdings has higher upside potential than Xtant Medical Holdings, analysts believe Verano Holdings is more attractive than Xtant Medical Holdings.

Verano Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.124, suggesting its less volatile than the S&P 500 by 112.425%.

Verano Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verano Holdings pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Verano Holdings quarterly revenues are $218.2M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. Verano Holdings's net income of -$272.7M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, Verano Holdings's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verano Holdings is 0.29x versus 0.61x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.